{"id":51868,"date":"2025-12-23T21:13:12","date_gmt":"2025-12-23T13:13:12","guid":{"rendered":"https:\/\/flcube.com\/?p=51868"},"modified":"2025-12-23T21:13:13","modified_gmt":"2025-12-23T13:13:13","slug":"aosaikangs-delafloxacin-wins-nmpa-approval-as-first-fluoroquinolone-for-china-infections","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51868","title":{"rendered":"Aosaikang\u2019s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections"},"content":{"rendered":"\n

Beijing Aosaikang Pharmaceutical Co., Ltd.<\/strong> (SHE: 002755<\/a>) announced that China\u2019s National Medical Products Administration (NMPA)<\/strong> approved its delafloxacin meglumine<\/strong> for the treatment of acute bacterial skin and skin structure infections (ABSSSI)<\/strong> and community\u2011acquired bacterial pneumonia (CABP)<\/strong>. The drug, a new\u2011generation broad\u2011spectrum antimicrobial<\/strong>, is the first and only delafloxacin product<\/strong> in China, filling a domestic market gap.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Approval Date<\/strong><\/td>23\u202fDec\u202f2025<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Product<\/strong><\/td>Delafloxacin meglumine<\/td><\/tr>
Indications<\/strong><\/td>ABSSSI and CABP<\/td><\/tr>
Drug Class<\/strong><\/td>Category\u202f3 chemical drug<\/td><\/tr>
Innovation<\/strong><\/td>First delafloxacin<\/strong> approved in China<\/td><\/tr>
Global Reference<\/strong><\/td>Baxdela (Melinta), FDA\u2011approved June\u202f2017 (ABSSSI) and Oct\u202f2019 (CABP)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Competitive Advantage<\/h2>\n\n\n\n
Attribute<\/th>Delafloxacin<\/th>Competitive Context<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>New\u2011generation broad\u2011spectrum antimicrobial<\/td>Active against G+, G\u2011, and anaerobic bacteria<\/td><\/tr>
Formulation<\/strong><\/td>Oral and IV (not specified in announcement)<\/td>Cost\u2011effective vs. branded Baxdela<\/td><\/tr>
Differentiation<\/strong><\/td>First domestic delafloxacin<\/strong><\/td>Fills China market gap; no competitors locally<\/td><\/tr>
Clinical Data<\/strong><\/td>Completed confirmatory studies<\/td>Supports Category\u202f3 registration pathway<\/td><\/tr>
Pricing Strategy<\/strong><\/td>Generic pricing with innovation premium<\/td>30\u201140% discount to imported Baxdela expected<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
China ABSSSI\/CABP Market<\/strong><\/td>\u00a515\u201120\u202fbillion<\/strong> (\u2248\u202fUS$2.1\u20112.8\u202fB)<\/td>Dominated by fluoroquinolones and \u03b2\u2011lactams<\/td><\/tr>
Delafloxacin Peak Sales<\/strong><\/td>\u00a5500\u2011800\u202fmillion<\/strong> (\u2248\u202fUS$70\u2011112\u202fM) by 2030<\/td>5\u20118% share of broad\u2011spectrum segment<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Limited novel antibiotics; rising resistance<\/td>Delafloxacin addresses unmet need<\/td><\/tr>
Launch Timeline<\/strong><\/td>Q2\u202f2026 (hospital formulary placement)<\/td>Leverages existing Aosaikang distribution network<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n